Brokerages Set Aldeyra Therapeutics, Inc (ALDX) Target Price at $32.25

Shares of Aldeyra Therapeutics, Inc (NASDAQ:ALDX) have been assigned a consensus rating of “Buy” from the eight brokerages that are currently covering the firm, Marketbeat reports. One research analyst has rated the stock with a sell rating, two have issued a hold rating and five have given a buy rating to the company. The average 1-year price target among brokerages that have updated their coverage on the stock in the last year is $32.25.

Several equities analysts have recently issued reports on the company. Zacks Investment Research lowered Aldeyra Therapeutics from a “hold” rating to a “sell” rating in a research note on Tuesday, July 17th. ValuEngine raised Aldeyra Therapeutics from a “buy” rating to a “strong-buy” rating in a research note on Friday, August 10th. Cantor Fitzgerald set a $23.00 price target on Aldeyra Therapeutics and gave the company a “buy” rating in a research note on Thursday, August 9th. Canaccord Genuity reaffirmed a “buy” rating and set a $27.00 price target on shares of Aldeyra Therapeutics in a research note on Friday, August 10th. Finally, Janney Montgomery Scott upped their price target on Aldeyra Therapeutics to $28.00 and gave the company a “positive” rating in a research note on Thursday, September 27th.

Shares of ALDX stock traded down $0.05 during trading hours on Monday, hitting $11.00. 111,628 shares of the company’s stock were exchanged, compared to its average volume of 244,971. The company has a debt-to-equity ratio of 0.03, a quick ratio of 8.11 and a current ratio of 8.11. The stock has a market capitalization of $218.56 million, a PE ratio of -7.86 and a beta of 0.86. Aldeyra Therapeutics has a 52 week low of $5.55 and a 52 week high of $16.70.

Aldeyra Therapeutics (NASDAQ:ALDX) last announced its earnings results on Thursday, August 9th. The biotechnology company reported ($0.46) EPS for the quarter, missing the consensus estimate of ($0.43) by ($0.03). As a group, analysts forecast that Aldeyra Therapeutics will post -1.77 earnings per share for the current fiscal year.

Large investors have recently added to or reduced their stakes in the business. National Asset Management Inc. acquired a new position in Aldeyra Therapeutics in the third quarter valued at about $193,000. Rhumbline Advisers acquired a new position in Aldeyra Therapeutics in the second quarter valued at about $113,000. Schwab Charles Investment Management Inc. acquired a new position in Aldeyra Therapeutics in the second quarter valued at about $237,000. Essex Investment Management Co. LLC acquired a new stake in shares of Aldeyra Therapeutics during the second quarter worth about $312,000. Finally, Mesirow Financial Investment Management Inc. acquired a new stake in shares of Aldeyra Therapeutics during the second quarter worth about $327,000. 57.92% of the stock is currently owned by hedge funds and other institutional investors.

About Aldeyra Therapeutics

Aldeyra Therapeutics, Inc, a biotechnology company, focuses on the development of products for inflammation, inborn errors of metabolism, and other diseases in the United States and internationally. It is developing ADX-102, a small molecule designed to trap and allow for the degradation of aldehydes, as well as ADX-103 and ADX-104 novel candidates for the treatment of noninfectious anterior uveitis, allergic conjunctivitis, dry eye syndrome, sjögren-larsson syndrome, and succinic semi-aldehyde dehydrogenase deficiency.

Featured Article: Bond

Analyst Recommendations for Aldeyra Therapeutics (NASDAQ:ALDX)

Receive News & Ratings for Aldeyra Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aldeyra Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply